Tuesday, May 21, 2019 12:24 AM
VANCOUVER—A recent study found that optometrists remain split on the impact of blue light from electronic devices, such as computer and phone screens, and the effectiveness of blue light-blocking devices, according to reporting by Patrick Campbell in MD Magazine
. The study, titled “Insights into Australian optometrists’ knowledge and attitude toward prescribing blue light-blocking ophthalmic devices,” was published in the Journal of the College of Optometrists
and presented at the 2019 meeting of the Association for Research in Vision and Ophthalmology
(ARVO) held here recently.
Tuesday, May 21, 2019 12:21 AM
TARRYTOWN, N.Y.—Regeneron Pharmaceuticals
(NASDAQ: REGN) announced on May 13 that the U.S. Food and Drug Administration (FDA) has approved EYLEA Injection to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness. “Millions of people have been robbed of their vision due to the progression of diabetic retinopathy,” said David Brown, MD, FACS, an investigator for the Panorama trial and director of research at retina consultants of Houston. "The prevention of worsening diabetic retinopathy with EYLEA provides a compelling rationale for early treatment of patients with this disease, particularly since eyes dosed with EYLEA as infrequently as every 16 weeks showed significant improvements in the pivotal Panaroma trial.”
Wednesday, March 6, 2019 12:27 AM
DALLAS—Eyecare Services Partners
(ESP), a leader in integrated eyecare services, has appointed George Neal as chief executive officer, effective March 4. Neal was previously chief executive officer of Access Dental, a dental services organization that was recently sold by Guardian Life Insurance Company of America. He succeeds former chief executive officer Michael Fricke, who has retired, a spokesman told VMAIL
. In addition, ESP has named Aaron Cho—a former colleague of Neal’s—as chief financial officer and Roberto Conte as vice president, operations–east.
Friday, February 8, 2019 12:30 AM
CINCINNATI—CEI Vision Partners
(CVP), a portfolio company of Revelstoke Capital Partners LLC , a Denver-based private equity firm, has completed a partnership with Virginia Eye Consultants
(VEC) , a premier multi-specialty ophthalmology group comprised of 17 providers that service the Norfolk, Virginia Beach and Chesapeake markets through four clinic locations and an ambulatory surgery center.
Wednesday, December 12, 2018 12:18 AM
LONDON—Moorfields Eye Hospital NHS Foundation Trust
has successfully bid for government funding to support Oriel, a proposal to design, build and operate a new, integrated eyecare research and education facility, according to an announcement by the hospital late last week. Moorfields has managed to secure nearly £20 million of funding as part of the Department of Health & Social Care’s major investment in the long-term future of the NHS, the announcement noted. Oriel will relocate all services from Moorfields Eye Hospital on City Road and the UCL Institute of Ophthalmology on Bath Street to the new facility at its preferred site at St. Pancras Hospital, the announcement noted.
Wednesday, October 31, 2018 12:21 AM
GREENBELT, Md.—The Retina Group of Washington
(RGW), a leading provider of retinal and macular care in the Washington, D.C., metropolitan area, has announced plans to merge with Retina Associates
(RA), a five-office practice operating in suburban Maryland locations. The merger of the two firms will be effective Jan. 1, according to the announcement earlier this month. The terms of the transaction were not disclosed. RGW currently has 14 offices in Maryland, Virginia and Washington, D.C., and totals 26 full-time physicians who provide expertise in a variety of retina-related sub-specialties, according to the announcement.
Wednesday, October 17, 2018 12:21 AM
, a leading multi-specialty ophthalmology platform and a portfolio company of Chicago Pacific Founders
, has announced a strategic partnership with Mid Island Eye Physicians & Surgeons
. The partnership adds five physicians and one location in Bethpage, N.Y., to SightMD’s team of more than 50 physicians working across 25 locations in New York, according to the announcement. SightMD is backed by Chicago Pacific Founders, a leading middle-market private equity firm that focuses exclusively on partnerships with companies in health care services.
Tuesday, October 16, 2018 12:24 AM
CINCINNATI—CEI Vision Partners
(CVP), a leading ophthalmology services organization formed by Cincinnati Eye Institute and Revelstoke Capital Partners, has acquired Dayton Eye Associates
in Dayton, Ohio. This is the first acquisition for CVP since it was formed in May 2018, according to an announcement late last week. The terms of the deal were not disclosed. Cincinnati Eye Institute
(CEI), one of the largest ophthalmology practices in the country, announced the formation of CEI Vision Partners in partnership with Denver-based Revelstoke Capital Partners
in May, as VMAIL reported
Tuesday, September 18, 2018 12:05 AM
NEW YORK—Three years ago, as ocular telehealth began to attract widespread attention throughout the eyecare industry, the focus was largely on “store and forward” technology, which involves collecting clinical information and sending it electronically to another site for evaluation, and the then new technology of visual acuity testing via computer or smartphone.
Wednesday, September 12, 2018 12:30 AM
HAUPPAUGE, N.Y. and CHICAGO—SightMD
and Chicago Pacific Founders Fund LP
(CPF) said they are entering into a partnership to expand SightMD’s patient-centric care model.
Wednesday, September 12, 2018 12:24 AM
FORT WORTH, Texas—Eyevance Pharmaceuticals
, a Fort Worth-based pharmaceutical company, has acquired the Freshkote family of lubricant eye drops from Focus Laboratories
. Under the terms of the agreement, Eyevance acquired Freshkote and all its formulations, including the preservative-free, multi-dose bottle and single-unit vials, to market and commercialize worldwide. The financial terms of the agreement were not disclosed. “The acquisition of the Freshkote franchise represents an important business milestone for Eyevance, which is actively building a portfolio of impactful and innovative eyecare products, focused on the anterior segment of the eye,” said Jerry St. Peter, CEO and director, Eyevance.
Thursday, September 6, 2018 12:21 AM
WATERTOWN, Mass.—EyePoint Pharmaceuticals
(NASDAQ:EYPT), a specialty biopharmaceutical company working to develop innovative ophthalmic products, reported Wednesday that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through status and reimbursement through a C-code for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is an FDA-approved product for treating postoperative inflammation. It is administered as a single intraocular dose at the end of ocular surgery, according to EyePoint’s announcement. The code, C9034, will become effective Oct. 1, 2018, the company said.
Thursday, September 6, 2018 12:15 AM
GAINESVILLE, Fla.—University of Florida Health
announced that ophthalmology researcher William Hauswirth, PhD and his collaborators are sharing in a $1.2 million international award for developing a sight-restoring treatment for people who have a genetic form of vision loss. The 2018 Antonio Champalimaud Vision Award
recognizes Hauswirth and his colleagues for developing the first successful gene therapy to cure an inherited human disease. The disease, Leber congenital amaurosis Type 2, or LCA 2, is caused by a genetic defect.
Thursday, August 30, 2018 12:18 AM
on Wednesday announced an “immediate, voluntary market withdrawal” of the CyPass Micro-Stent from the global market. The company said the decision is based, in part, on its “uncompromising commitment to patient safety.” In addition, Alcon advised surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. “This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study,” the announcement noted. Alcon, the eyecare unit of Novartis, is expected to become an independent publicly traded company after a spinoff by its corporate parent in early 2019, as VMAIL
Wednesday, August 29, 2018 12:15 AM
WATERLOO, Ontario—OcuBlink, Inc.
, which is developing sophisticated in vitro eye models for ophthalmic testing, has received funding from two business accelerators. The company will use the funds and associated entrepreneurial coaching to scale its business, which focuses on assisting research centers, pharmaceutical and medical device companies validate ocular products more rapidly and cost effectively, according to an announcement earlier this month. AC JumpStart
, funded by FedDev Ontario, awarded OcuBlink $30,000 (Canadian dollars) in seed capital and $10,000 of in-kind mentorship. The accelerator helps technology start-ups establish and grow their business in Southern Ontario.